{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T21:40:10Z","timestamp":1759095610848,"version":"3.44.0"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2022JJ30533"],"award-info":[{"award-number":["2022JJ30533"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ijcard.2022.10.149","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T01:23:20Z","timestamp":1666661000000},"page":"367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Febuxostat, a potential drug in the secondary prevention of cardiovascular disease with hyperuricemia"],"prefix":"10.1016","volume":"370","author":[{"given":"Can","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2022.10.149_bb0005","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijcard.2021.11.076","article-title":"Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease","volume":"349","author":"Konishi","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2022.10.149_bb0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12933-016-0409-2","article-title":"Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study","volume":"15","author":"Oyama","year":"2016","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ijcard.2022.10.149_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075527","article-title":"Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase-1-mediated inactivation of JNK","volume":"8","author":"Nomura","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijcard.2022.10.149_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20194680","article-title":"Xanthine oxidase inhibitor Febuxostat exerts an anti-inflammatory action and protects against diabetic nephropathy development in KK-ay obese diabetic mice","volume":"20","author":"Mizuno","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijcard.2022.10.149_bb0025","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/cpt.1377","article-title":"Hypersensitivity and cardiovascular risks related to allopurinol and Febuxostat therapy in Asians: a population-based cohort study and Meta-analysis","volume":"106","author":"Chen","year":"2019","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527322016606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527322016606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T21:02:34Z","timestamp":1759093354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527322016606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":5,"alternative-id":["S0167527322016606"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2022.10.149","relation":{},"ISSN":["0167-5273"],"issn-type":[{"type":"print","value":"0167-5273"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Febuxostat, a potential drug in the secondary prevention of cardiovascular disease with hyperuricemia","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2022.10.149","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}